ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2100 • 2016 ACR/ARHP Annual Meeting

    Pharmaceutical Disruption of B2GPI CXCL4 Complex Using Computationally Designed Oligopeptides

    Markos Patsouras1, Elenh Papakonstantinou2, Elias Eliopoulos2 and Panayiotis G Vlachoyiannopoulos1, 1School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece, 2Department of Biotechnology, Agricultural University of Athens, ATHENS, Greece

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by recurrent thromboembolism and or pregnancy morbidity in the presence of antiphospholid antibodies (aPL). Major auto…
  • Abstract Number: 2101 • 2016 ACR/ARHP Annual Meeting

    the Association Between ABO Blood Types and Venous Thromboembolism in Individuals with a Positive Antiphospholipid Antibody Profile Is Varied By Sex

    Michael Shusterman1, Eugeniya Golub1, Wenzhu Mowrey2 and Anna R. Broder3, 1Medicine, Montefiore Health Systems, Bronx, NY, 2Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 3Medicine/Rheumatology, Division of Rheumatology, Albert Einstein College of Med, Bronx, NY

    Background/Purpose: Venous thrombotic events (VTE) are the most common complications in patients with persistently positive aPL antibodies (aPL+)1 . The pathogenesis of VTE is multifactorial,…
  • Abstract Number: 2102 • 2016 ACR/ARHP Annual Meeting

    the Prevalence and Associations of IgG/a/M ANTI-β2GPI and ANTI-Domain I  Antibodies in an Antiphospholipid Syndrome (APS) Cohort of Patients from Turkey

    Bahar Artim-Esen1, Thomas McDonnell2, Charis Pericleous3, Ozlem Pehlivan4, Murat Inanc5, Ian Giles6 and Anisur Rahman2, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, 3Imperial College Vascular Sciences, National Heart and Lung Institute, Imperial College Vascular Sciences, National Heart and Lung Institute, London, United Kingdom, 4Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey, 5Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, 6Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom

    Background/Purpose:   Methods:   Results:   Conclusion:   All patients (n=75) Vascular Thrombosis only (n=15) P IgG anti-β2GPI 17% 19% 14% NS IgA anti-β2GPI 36%…
  • Abstract Number: 2103 • 2016 ACR/ARHP Annual Meeting

    Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis

    Meredyth Wilkinson1, Christopher Piper2, Georg Otto3, Claire Deakin4, Stefanie Dowle3, Stefania Simou5, Daniel Kelberman3, Yiannis Ioannou6, Claudia Mauri7, Elizabeth Jury8, David Isenberg9, Lucy R Wedderburn10 and Kiran Nistala11, 1Division of Medicine, University College London, London, United Kingdom, 2Rheumatology, University College London, London, United Kingdom, 3National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 4Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, 5Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, 6Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 7Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom, 8Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, 9University College Hospital, London, London, United Kingdom, 10Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, 11Centre for Rheumatology, University College London, London, United Kingdom

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare form of childhood autoimmune myositis that presents with proximal muscle weakness and heliotrope rash. B cells are strongly…
  • Abstract Number: 2104 • 2016 ACR/ARHP Annual Meeting

    Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis

    Nekane Terrades-Garcia1, Joana Daradoumis2, Ester Planas-Rigol2, Marc Corbera-Bellalta1, Sergio Prieto-González2, Georgina Espígol-Frigolé2 and Maria C. Cid3, 1Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain

    Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…
  • Abstract Number: 2105 • 2016 ACR/ARHP Annual Meeting

    Autoimmune Pancreatitis-Associated Autoantigens Among 100 IgG4-Related Diseases Patients

    Cory A. Perugino1,2, Imad Awan2, Ian Rosenberg2, Vinay Mahajan2, John H. Stone1 and Shiv Pillai2, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder of uncertain etiology. Recognition of this disease as a distinct entity stemmed from investigation into autoimmune pancreatitis…
  • Abstract Number: 2106 • 2016 ACR/ARHP Annual Meeting

    Regulation of Marginal Zone B Cell Differentiation By microRNA-146a

    Jennifer K. King1, May Paing2, Nolan Ung2, Jorge Contreras2, Michael Alberti2, Thilini Fernando2, Kelvin Zhang2, Matteo Pellegrini2 and Dinesh Rao2, 1Medicine, Rheumatology, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, CA

    Background/Purpose: B cell development in the bone marrow is followed by specification into several functional subsets in the spleen, including marginal zone B (MZB) cells…
  • Abstract Number: 2107 • 2016 ACR/ARHP Annual Meeting

    Targeting Mir-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production

    Mariola Kurowska-Stolarska1, Iain B McInnes2, Stefano Alivernini3, Aziza Elmesmari4, Gianfranco Ferraccioli5, James Reilly2 and David W. McCarey6,7, 1Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 5Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 6Glasgow Royal Infirmary, Glasgow, United Kingdom, 7Centre for Rheumatic Diseases, Centre for Rheumatic Diseases, Glasgow, United Kingdom

    Background/Purpose: Better understanding of epigenetic regulatory mechanisms in RA pathogenesis will facilitate the development of new biomarkers or therapeutic strategies.  MicroRNAs are post-transcriptional regulators that…
  • Abstract Number: 2108 • 2016 ACR/ARHP Annual Meeting

    DNA Hypomethylation in Promoter Region of Zbtb38 Gene Ultimately Leads to Downregulated Expression of Anti-Inflammatory IL1r2 in Experiential Model of Rheumatoid Arthritis

    Timea Ocskó1, Daniel M. Tóth1, Attila Balog2, Katalin Mikecz1, Tibor T. Glant1 and Tibor A. Rauch3, 1Orthopedic Surgery, Rush University Medical Center, Chicago, IL, 2Rheumatology, Albert Szent-Gyorgyi University, Szeged, Hungary, 31735 W. Harrison Str., Rush University Medical Center, Chicago, IL

    Background/Purpose: Interleukin 1 beta (IL1B) is a multifunctional cytokine that is highly expressed in rheumatoid arthritis (RA) and drives pro-inflammatory pathways via interleukin 1 receptor…
  • Abstract Number: 2109 • 2016 ACR/ARHP Annual Meeting

    Immunoprofiling of Bruton’s Tyrosine Kinase (Btk)/Tec Family Kinase Inhibitors Indicate Activities Beyond Btk in Immunocyte Function

    Jolanta Kosek1, Lori Capone2, Mary Adams1, Eun Mi Hur1, Peter H. Schafer3 and Garth Ringheim1, 1Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, 2Celgene Corporation, Summit, NJ, 3Department of Translational Development, Celgene Corporation, Summit, NJ

    Background/Purpose:  CC-292, CC-90008, and ibrutinib are covalent Btk/Tec family kinase inhibitors that block Btk activity by binding with high affinity to the adenosine triphosphate (ATP)…
  • Abstract Number: 2110 • 2016 ACR/ARHP Annual Meeting

    Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)

    Torsten Lowin1, Matthias Schneider2 and Georg Pongratz3, 1Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, 2Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Düsseldorf, Germany, 3Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany

    Background/Purpose:  In rheumatoid arthritis (RA), synovial fibroblasts (SF) are one main contributor of joint destruction since they resist apoptosis and secrete pro-inflammatory cytokines and matrix…
  • Abstract Number: 2111 • 2016 ACR/ARHP Annual Meeting

    Generation and Characterization of Anti-Citrullinated Protein Antibody-Producing B-Cell Clones

    Kristine Germar1,2, Mark Kwakkenbos3, Sabrina Pollastro1,2, Nathalie van Uden1,2,4, Priscilla Kerkman5, Ellen I.H. van der Voort6, Evan Reed7, Karin Lundberg7, Niek de Vries1,8, Lars Klareskog7, Hans U. Scherer5, René E.M. Toes5, Arjen Bakker3, Hergen Spits3,9,10 and Dominique Baeten1,2,10, 1Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, 3AIMM Therapeutics, Amsterdam, Netherlands, 4Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 8Clinical Immunology and Rheumatology F4-105, Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, 9Department of Cell Biology and Histology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, 10These authors contributed equally to this work, Amsterdam, Netherlands

    Background/Purpose:  Rheumatoid arthritis (RA) is the most frequent form of autoimmune arthritis with a prevalence of almost 1% worldwide. Anti-citrullinated protein antibodies (ACPA) are the…
  • Abstract Number: 2112 • 2016 ACR/ARHP Annual Meeting

    Disease-Activity Associated Autoantibodies to Malondialdehyde-Modified Proteins Can be Isolated from Synovial B Cells in RA

    Caroline Grönwall1, Khaled Amara1, Uta Hardt1, Lelise Getu2, Jeffrey D. Greenberg3, Robert M Clancy3, Vivianne Malmström4 and Gregg J. Silverman3, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Department of Medicine, New York University School of Medicine, New York, NY, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 4Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Malondialdehyde (MDA) is a naturally occurring reactive aldehyde that arises during apoptosis or as a consequence of elevated reactive oxygen species and lipid peroxidation.…
  • Abstract Number: 2113 • 2016 ACR/ARHP Annual Meeting

    Anti-Carbamylated Protein Antibody (cross)-Reactivity Against Multiple Carbamylated Protein Antigens

    Marije K. Verheul1, Myrthe van Delft2, Tom WJ Huizinga1, REM Toes1 and LA Trouw1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose:   Antibodies that target carbamylated proteins (anti-CarP) have been implicated in rheumatoid arthritis and are known to associate with joint damage. Furthermore, these autoantibodies…
  • Abstract Number: 2114 • 2016 ACR/ARHP Annual Meeting

    Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity

    Jacqueline Dekkers1, Marije K. Verheul2, Jeroen Stoop3, Bisheng Liu4, Peter A. van Veelen5, Martin Hegen6, Stephen Rapecki7, Tom WJ Huizinga2, Leendert A. Trouw4 and René Toes4, 1Rheumatology, Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Center (LUMC), Leiden, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, 6Inflammation, Wyeth Pharmaceuticals, Cambridge, MA, 7UCB Pharma, Slough, United Kingdom

    Background/Purpose: Autoantibodies are an important hallmark of Rheumatoid Arthritis (RA). Approximately 50% of RA patients harbor anti-carbamylated protein (CarP) antibodies. These autoantibodies target proteins that…
  • « Previous Page
  • 1
  • …
  • 1737
  • 1738
  • 1739
  • 1740
  • 1741
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology